JPRN-UMIN000003516已完成未知
A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood. - A study of the efficacy of milnacipran in patients with major depressive disorder (MDD) after SSRI treatment failure, and biological research for MDD using peripheral blood.
Department of Psychiatry, Chiba University Graduate School of Medicine, Division of Psychiatry, Chiba University Hospital0 个研究点目标入组 40 人开始时间: 2010年4月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) treating with selegiline hydrochloride 2) Allergy against milnacipran 3) patients with urinary retension 4) pregnant or breast-feeding women or women, who may be pregnant 5) significant risk of suicide 6) patients with dementia, bipolar or psychotic disorders, those with a primary diagnosis of obsessive-compulsive disorder or an eating disorder. 7) Patient whom examination doctor judge improper as a trial subject
研究者
相似试验
已完成
3 期
Study of Milnacipran for the Treatment of FibromyalgiaFibromyalgiaNCT00314249Forest Laboratories1,025
已完成
4 期
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of FibromyalgiaFibromyalgiaNCT01077375Forest Laboratories107
已完成
4 期
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of FibromyalgiaFibromyalgiaNCT01014585Forest Laboratories340
未知
4 期
A postmarketing clinical study of milnacipran hydrochloride (MIL001) for the treatment of depressioMajor depressionJPRN-jRCT1080220706ASAHI KASEI PHARMA CORPORATIO705
终止
3 期
Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly PopulationFibromyalgiaNCT01418651Banner Health20